The relationship between efficacy and potency is a key concept in understanding psychedelic drug pharmacology.
MindMed just started a Phase 1 trial which is studying the effects of LSD + MDMA administered together.
“We have some [compounds] now that are unlike anything you’ve ever seen before.”
A recent study shows DMT reduces the cellular stress caused by a stroke and speeds up recovery time in rats. These findings highlight the expanding therapeutic potential of DMT regarding neurological disorders.
For humans, drug doses are based largely on body weight. But in animals, differences in brain and body chemistry make the calculations far more complicated.
Integrating several tests into a SAR, scientists have identified the compound 2C-H as a structural basis of the anti-inflammatory response in rats.
The first trial will determine the sublingual dose equivalent to 25 mg psilocybin administered orally.
The researchers hope these compounds “will expand the universe of options for improving mental health.”
The research will use cutting-edge technology to attempt to remove undesirable side-effects from drugs targeting GPCRs, including the serotonin receptors where psychedelics act.
“In the pharmaceutical drug development community, this is what you dream about.”